Growth hormone-releasing hormone (GHRH) analogue
CJC-1295
A GHRH analogue sold in two distinct forms that share a name. The DAC variant carries an albumin-binding group and differs from the non-DAC form in formula, mass and CAS number.
Also listed as: CJC-1295 DAC, DAC:GRF, Modified GRF (1-29), Mod GRF 1-29
Chemical identity
- Compound class
- Growth hormone-releasing hormone (GHRH) analogue. Supplied in two chemically distinct forms
- Sequence
- With DAC: modified GRF(1-29) backbone with Lys30 bearing a 3-(maleimido)propanoyl albumin-binding group. Without DAC: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
- Molecular formula
- With DAC: C165H269N47O46 · Without DAC: C152H252N44O42
- Molecular weight
- With DAC: 3647.2 g/mol · Without DAC: 3367.9 g/mol
- CAS number
- With DAC: 446262-90-4 · Without DAC: 863288-34-0
- PubChem CID
- 91971820 (with DAC) · 56841945 (without DAC)
- Research categories
- GHRH analogues
United States regulatory status
No FDA-approved product
- No approved drug product exists in Drugs@FDA for either form.
- Listed on FDA's table of bulk substances nominated for compounding and withdrawn by the nominator. FDA's entry does not distinguish between the DAC and non-DAC forms.
- FDA's published concerns reference serious adverse events reported in association with CJC-1295, including increased heart rate and systemic vasodilatory reaction.
Anti-doping status
Named at S2.2.4 among GHRH analogues. Prohibited at all times; non-Specified.
Regulatory status describes how a substance is classified. It is not a safety assessment, and it says nothing about the quality of any particular material.
Sources
Last reviewed 3 September 2026 · Compiled by Therapept Editorial · How these records are built